Risk assessment: Controversies and management of moderate- to high-risk individuals

Breast Journal

Volumn 11, Issue SUPPL. 1, 2005, Pages

  Brown, Powel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

BRCA 1; BRCA 2; Breast cancer; Chemoprevention; Genetics; Risk assessment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; RETINOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; BEHAVIOR MODIFICATION; BREAST CARCINOMA; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CASE REPORT; CLINICAL TRIAL; CONFERENCE PAPER; FAMILIAL CANCER; FEMALE; GAIL MODEL; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MODEL; PATIENT SELECTION; PHYSICIAN ATTITUDE; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT PLANNING; UTERUS CARCINOMA;

ADULT; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; PATIENT CARE MANAGEMENT; RISK ASSESSMENT;

EID: 15944390925     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2005.217163.x     Document Type: Conference Paper

References (48)

1. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25.
2. Kriege M, Brekelmans CT, Boetes C, et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
3. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the life interplay of genes, lifestyle, and hormones. Breast Cancer Res 2004;6:213-18.
4. Sundquist M, Thorstenson S, Brudin L, Wingren S, Nordenskjold B. Incidence and prognosis in early onset breast cancer. Breast 2002;11:30-35.
5. Biglia N, Nefabiani E, Ponzone R, Mariani L, Marenco D, Sismondi P. Management of risk of breast carcinoma in postmenopausal women. Endocr Relat Cancer 2004;11:69-83.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
9. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
10. Jensen RA, Page DL. Ductal carcinoma in situ of the breast: impact of pathology on therapeutic decisions. Am J Surg Pathol 2003;27:828-31.
11. Page DL. Breast lesions, pathology and cancer risk. Breast J 2004;10(suppl 1):S3-4.
12. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
13. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
14. Michels KB, Ekbom A. Caloric restriction and incidence of breast cancer. JAMA 2004;291:1226-30.
15. Kushi L, Giovannucci E. Dietary fat and cancer. Am J Med 2002;113(suppl 9B):S63-70.
16. Lagerros YT, Hsieh SF, Hsieh CC. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review. Eur J Cancer Prev 2004;13:5-12.
17. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
18. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat 1993;28:115-20.
19. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptible genes. J Clin Oncol 2002;20:2701-12.
20. McTiernan A. Behavioral risk factors in breast cancer: can risk be modified? Oncologist 2003;8:326-34.
21. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
22. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
23. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999;282:637-45.
24. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
25. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002;360:817-24.
26. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
27. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-97.
28. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-65.
29. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
30. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC trial and the design of IBIS-II. Recent Results Cancer Res 2003;163:96-103; discussion 264-66.
31. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-39.
32. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
33. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
34. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001;93:1633-37.
35. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
36. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
37. Friedman GD, Ury HK. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst 1980;65:723-33.
38. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
39. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000;83:112-30.
40. Shim V, Gauthier ML, Sudilovsky D, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003;63:2347-50.
41. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
42. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000;60:2101-3.
43. Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004;4:180-88.
44. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069(Targretin): an RXR-selective ligand. Cancer Res 1996;56:5566-70.
45. Wu K, Kim HT, Rodriquez JL, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002;11:467-74.
46. Wu K, Zhang Y, Xu X-C, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res 2002;62:6376-80.
47. Suh N, Lamph WW, Glasebrook AL, et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin Cancer Res 2002;8:3270-75.
48. Rendi MH, Suh N, Lamph WW, et al. The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. Cancer Res 2004;64:3566-71.